Calendario›VTVT›Cadisegliatin 800 mg QD · Hybrid CATT1

Cadisegliatin 800 mg QD · Hybrid CATT1

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

Ensayo de vTv Therapeutics Inc. en Type 1 Diabetes (T1D) (del registro, en inglés).

Fase

Fase 2

Estado

Aún sin reclutar

Participantes

40

previstos

Centros

1

Fin del objetivo primario

jun 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en oct 2026.

Lo que ha cambiado

Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.

Qué mide

To assess the change in Time in Range (TIR) (last 2 weeks of the two 6-week treatment periods) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroTTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.

Más ensayos de VTVT

Todos los de VTVT, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07616206), actualizada en sep 2026.